[]
Barenberg P., Strahlendorf H., Strahlendorf J.: Hypoxia induces an
excitotoxic – type of dark cell degeneration in cerebellar Purkinje
neurons. Neurosci Res 2001; 40: 245–254.
[]
Löscher W.: Valproinsäure. Pharmakodynamische Wirkungen und
biochemische Wirkungsmechanismen. [w:] Krämer G., Laub M. [red.]:
Valproinsäure. Springer Verlag, Berlin-Heidelberg-NY 1992.
[]
Adkison K.D., Ojemann G.A., Rapport R.L., et al.: Distribution of
unsaturated metabolites of valproate in human and rat brain –
pharmacologic relevance? Epilepsia 1995; 36: 772–782.
[]
Lukoyanov N.V., Madeira M.D., Paula-Barbosa M.M.: Behavioral
and neuroanatomical consequences of chronic ethanol intake and
withdrawal. Physiol Behav 1999; 66: 337–346.
[]
Lundqvist C., Alling C., Knoth R., et al.: Intermittent ethanol exposure of
adult rats: hippocampal cell loss after one month of treatment. Alcohol
Alcohol 1995; 30: 737–748.
[]
Franke H., Kittner H., Berger P., et al.: The reaction of astrocytes and
neurons in the hippocampus of adult rats during chronic ethanol
treatment and correlations to behavioral impairments. Alcohol 1997; 14:
445–454.
[]
Jiang W., Duong T.M., de Lanerolle N.C.: The neuropathology of
hyperthermic seizures in the rat. Epilepsia 1999; 40: 5–19.
[]
Sendrowski K., Sobaniec W., Sobaniec-Lotowska M.E., et al.: Topiramate
as a neuroprotectant in the experimental model of febrile seizures. Adv
Med Sci. 2007; 52 (Suppl 1): 161–165.
[]
Fritschy J.M., Kiener T., Bouilleret V., et al.: GABAergic neurons and
GABA(A)-receptors in temporal lobe epilepsy. Neurochem Int 1999; 34:
435–445.
[]
Desphande J., Bergstedt K., Linden T., et al.: Ultrastructural ges in
the hippocampal CA1 region following transcient cerebral ischemia:
evidence against programmed cell death. Exp Brain Res 1992; 88:
91–105.
[]
Fukuda T., Wang H., Nakanishi H., et al.: Novel non-apoptotic
morphological changes in neurons of the mouse hippocampus following
transient hypoxic-ischemia. Neurosci Res 1999; 33: 49–55.
[]
Sobaniec W., Jankowicz E., Sobaniec-Łotowska M.: The effect of
valproic acid on the morphology of the rat cerebellum and brain stem.
Neuropat Pol 1989; 27: 137–150.
[]
Bikashvili T.Z., Shukakidze A.A., Kiknadze G.I.: Changes in the rat cerebral
cortex ultrastructure following peroral administration of manganese
chloride. Morfologiia 2000; 118: 14–18.
[]
Bergman A., Feigenbaum J.J., Yanai J.: Neuronal losses in mice
following both prenatal and neonatal exposure to phenobarbital. Acta
Anat (Basel) 1982; 114: 185–192.
[]
Liu Z., Nagao T., Desjardins G.C., et al.: Quantitative evaluation
of neuronal loss in the dorsal hippocampus in rats with long-term
pilocarpine seizures. Epilepsy Res 1994; 17: 237–247.
[]
Miettinen R., Kotti T., Tuunanen J., et al.: Hippocampal damage after
injection of kainic acid into the rat entorhinal cortex. Brain Res 1998;
813: 9–17.
[]
Fujikawa D.G., Shinmei S.S., Cai B.: Seizure – induced neuronal necrosis:
implications for programmed cell death mechanisms. Epilepsia 2000; 41:
9–13.
[]
Cavazos J.E., Das I., Sutula T.P.: Neuronal loss induced in limbic
pathways by kindling: evidence for induction of hippocampal sclerosis
by repeated brief seizures. J Neurosci 1994; 14: 3106–3121.
[]
Sagar H.J., Oxbury J.M.: Hippocampal neuronal loss in temporal lobe
epilepsy: correlation with early childhood convulsions. Ann Neurol 1987;
22: 334–340.
[]
Kim J.H., Guimaraes P.O., Shen M-Y., et al.: Hippocampal neuronal density
in temporal lobe epilepsy with and without gliomas. Acta Neuropathol
1990; 80: 41–45.
[]
Sendrowski K., Sobaniec W., Sobaniec P., et al.: Ultrastructural study
of hippocampal cortex neurons in an experimental model of valproate
encephalopathy. Folia Histochem Cytobiol 2013; 51: 31–37.
[]
Chopra A., Kolla B.P., Mansukhani M.P., et al.: Valproate-induced
hyperammonemic encephalopathy: an update on risk factors, clinical
correlates and management. Gen Hosp Psychiatry 2012; 34: 290–298.
[]
Jóźwiak S., Kotulska K.: Aktualne rekomendacje w leczeniu padaczki
i zespołów padaczkowych u dzieci i młodzieży. Neurol Dziec 2010; 38:
11– 18.
[]
Haddad P.M., Das A., Ashfag M., et al.: A review of valproate in
psychiatric practice. Expert Opin Drug Metab Toxicol 2009; 5: 539–551.
[]
Vikelis M., Rapoport A.M.: Role of antiepileptic drugs as preventive
agents for migraine. CNS Drugs 2010; 24: 21–33.
[]
Lux A.L.: Treatment of febrile seizures: historical perspective, current
opinions, and potential future directions. Brain Dev 2010; 32: 42–50.
[]
Gill D., Derry S., Wiffen P.J., et al: Valproic acid and sodium valproate for
neuropathic pain and fibromyalgia in adults. Cochrane Database Syst
Rev 2011; 10: CD009183.
[]
Witt D., Burfeind P., von Hardenberg S., et al.: Valproic acid inhibits the
proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis
2013; 34: 1115–1124.
[]
Jones G.L., Matsuo F., Baringer J.R., et al.: Valproic acid-associated
encephalopathy. West J Med 1990; 153: 199–202.
[]
Visticot F., Montreuil G.: Stupor encephalopathy caused by sodium
valproate. Rev Med Interne 1994; 15: 365–366.
[]
Kifune A., Kubota F., Shibata N., et al.: Valproic acid – induced
hyperammonemic encephalopathy with triphasic waves. Epilepsia 2000;
41: 909–912.
[]
Davis R., Peters D.H., McTavish D.: Valproic acid. A reappraisal of its
pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;
47: 332–372.
[]
Gobel R., Gortzen A., Braunig P.: Encephalopathies caused by valproate.
Fortschr Neurol Psychiatr 1999; 67: 7–11.
[]
Oechsner M., Steen C., Stürenburg H.J., et al.: Hyperammonemic
encephalopathy after initiation of valproate therapy in unrecognised
ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry
1998; 64: 680–682.
[]
Bourrier P., Varache N., Alquier P., et al.: Cerebral edema with
hyperammonemia in valpromide poisoning. Manifestation in an adult, of
a partial deficit in type I carbamylphosphate synthetase. Presse Med
1988; 17: 2063–2066.
[]
Chabrol B., Mancini J., Chretien D., et al.: Valproate-induced hepatic
failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 1994;
153: 133–135.
[]
Hou J.W., Chou S.P., Wang T.R.: Metabolic function and liver
histopathology in Reye-like illnesses. Acta Paediatr 1996; 85: 1053–
1057.
[]
Triggs W.J., Gilmore R.L., Millington D.S., et al.: Valproate-associated
carnitine deficiency and malignant cerebral edema in the absence of
hepatic failure. Int J Clin Pharmacol Ther 1997; 35: 353–356.
[]
Verrotti A., Greco R., Morgese G., et al.: Carnitine deficiency and
hyperammonemia in children receiving valproic acid with and without
other anticonvulsant drugs. Int J Clin Lab Res 1999; 29: 36–40.
[]
Averbuch-Heller L., Ben-Hur T., Reches A.: Valproate encephalopathy
and hypocarnitinaemia in diabetic patients. J Neurol 1994; 241: 567–
569.
[]
Rottach K.G., Weiss-Brummer J., Wieland U., et al.: Valproic acid
in prophylaxis of bipolar disorder. A case of valproate-induced
encephalopathy. Nervenarzt 2000; 71: 401–403.
Scholar Google
PubMed